Study Results Published in the Journal of Immunological Methods
CAMBRIDGE, Mass., Aug. 19, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease. The precise measurement of low abundance cytokines, which was possible using Quanterix's high sensitivity digital ELISA, allowed significant changes to be detected in patients before and after initiation of therapy. The study was published online in the Journal of Immunological Methods.
"Quanterix's digital ELISA enabled physiologically relevant concentrations of two important cytokines, TNF-alpha and IL-6, to be measured in plasma from all patient samples tested. Previous studies have not been able to quantify these biomarkers in all patients due to insufficient sensitivity," explained David Duffy, Ph.D., corresponding author of the study. "The inherent sensitivity of this technology also made it possible, for the first time, to accurately quantify changes in protein levels during the course of anti-TNF-alpha therapy. This work has important implications for patient management, including the ability to provide a quantitative index for how an individual is responding to therapy."
"Our collaboration with the Mayo Clinic is another example that highlights how unprecedented sensitivity enables important contributions to life science research and in vitro diagnostics," said Martin Madaus, Ph.D., Quanterix Executive Chairman. "Although larger studies will be needed to fully understand the potential utility of cytokine measurements in the diagnosis of inflammatory diseases such as Crohn's, these results provide some indication of how sensitive and precise protein measurements enabled by SiMoA could be used clinically."
Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness. Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.
SOURCE Quanterix Corporation